Mirati Therapeutics Inc
Change company Symbol lookup
Select an option...
MRTX Mirati Therapeutics Inc
CUZ Cousins Properties Inc
JRS Nuveen Real Estate Income Fund
GRTX Galera Therapeutics Inc
EVA Enviva Inc
SBLK Star Bulk Carriers Corp
TSP TuSimple Holdings Inc
GLG TD Holdings Inc
AGM-C Federal Agricultural Mortgage Corp
LICY Li-Cycle Holdings Corp
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Mirati Therapeutics Inc is a United States-based clinical-stage biotechnology company that is focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. The Company is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRASG12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. The Company is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRASG12D inhibitor, MRTX1719, an investigational PRMT5 inhibitor, and other oncology discovery programs.

Price
Delayed
$52.44
Day's Change
-1.82 (-3.35%)
Bid
--
Ask
--
B/A Size
--
Day's High
53.55
Day's Low
52.10
Volume
(Above Average)

Today's volume of 315,479 shares is on pace to be greater than MRTX's 10-day average volume of 1,262,122 shares.

315,479

Company Profile

Mirati Therapeutics Inc is a United States-based clinical-stage biotechnology company that is focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. The Company is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRASG12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. The Company is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRASG12D inhibitor, MRTX1719, an investigational PRMT5 inhibitor, and other oncology discovery programs.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
264.78x
Price/Book (MRQ)
2.77x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

January 2023
Current Month
10.6M
Previous Month
10.5M
Percent of Float
19.65%
Days to Cover
7.1083 Days

Share Information

MRTX is in a share class of common stock
Float
54.2M
Shares Outstanding
57.6M
Institutions Holding Shares
344
109.02%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Faheem Hasnain
  • Charles M. BaumPres.
  • David MeekCEO
  • Laurie D. StelzerCFO
  • Alan SandlerExec.VP

Address

Insider Trading

During the most recent quarter, 118K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.